{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:09:35Z","timestamp":1773317375096,"version":"3.50.1"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Atrium Wake Forest Baptist Health from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Erythropoietic protoporphyria (EPP) is a genetic disorder stemming from reduced ferrochelatase expression, the final enzyme in the pathway of heme biosynthesis. A closely related condition, X-linked protoporphyria (XLP), bears similar clinical features although it arises from the heightened activity of \u03b4-aminolevulinic acid synthase 2 (ALAS2), the first and normally rate-controlling enzyme in heme biosynthesis in developing red blood cells. Both of these abnormalities result in the buildup of protoporphyrin IX, leading to excruciating light sensitivity and, in a minority of cases, potentially fatal liver complications. Traditionally, managing EPP and XLP involved sun avoidance. However, the emergence of innovative therapies, such as dersimelagon, is reshaping the therapeutic landscape for these conditions. In this review, we summarize salient features of the properties of dersimelagon, shedding light on its potential role in advancing our understanding of treatment options for EPP and XLP.<\/jats:p>","DOI":"10.3390\/ph17010031","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T03:42:12Z","timestamp":1703475732000},"page":"31","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7484-7816","authenticated-orcid":false,"given":"Katelyn E.","family":"Madigan","sequence":"first","affiliation":[{"name":"Section on Gastroenterology & Hepatology, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean R.","family":"Rudnick","sequence":"additional","affiliation":[{"name":"Section on Gastroenterology & Hepatology, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Agnew","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Numra","family":"Urooj","sequence":"additional","affiliation":[{"name":"Department of Medicine, Parkview Health, Fort Wayne, IN 46845, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-3230","authenticated-orcid":false,"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[{"name":"Section on Gastroenterology & Hepatology, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102858","DOI":"10.1016\/j.pdpdt.2022.102858","article-title":"Bringing the gentle properties of daylight photodynamic therapy indoors: A systematic review of efficacy and safety","volume":"39","author":"Heerfordt","year":"2022","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102793","DOI":"10.1016\/j.pdpdt.2022.102793","article-title":"Cimetidine for erythropoietic protoporphyria","volume":"38","author":"Heerfordt","year":"2022","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_3","first-page":"671","article-title":"Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria","volume":"46","author":"Lim","year":"1989","journal-title":"Immunol. Ser."},{"key":"ref_4","first-page":"126","article-title":"Diminished erythroid ferrochelatase activity in protoporphyria","volume":"86","author":"Bottomley","year":"1975","journal-title":"J. Lab. Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI108189","article-title":"Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts","volume":"56","author":"Bonkowsky","year":"1975","journal-title":"J. Clin. Investig."},{"key":"ref_6","first-page":"104","article-title":"Overview of liver involvement in patients with erythropoietic protoporphyria","volume":"19","author":"Levy","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.1994.tb08577.x","article-title":"Erythropoietic protoporphyria","volume":"131","author":"Todd","year":"1994","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cge.12562","article-title":"X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria","volume":"89","author":"Brancaleoni","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2119\/molmed.2012.00340","article-title":"Porphyrias Consortium of the National Institutes of Health Rare Diseases Clinical Research Network: Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria","volume":"19","author":"Balwani","year":"2013","journal-title":"Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ymgme.2019.01.020","article-title":"Erythropoietic protoporphyria and X-linked protoporphyria: Pathophysiology, genetics, clinical manifestations, and management","volume":"128","author":"Balwani","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Di Pierro, E., Granata, F., De Canio, M., Rossi, M., Ricci, A., Marcacci, M., De Luca, G., Sarno, L., Barbieri, L., and Ventura, P. (2022). Recognized and emerging features of erythropoietic and X-linked protoporphyria. Diagnostics, 12.","DOI":"10.3390\/diagnostics12010151"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V62.4.846.846","article-title":"Light-induced release of protoporphyrin, but not of zinc protoporphyrin, from erythrocytes in a patient with greatly elevated erythrocyte protoporphyrin","volume":"62","author":"Sandberg","year":"1983","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1056\/NEJMoa2208754","article-title":"Dersimelagon in Erythropoietic Protoporphyrias","volume":"388","author":"Balwani","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41436-020-00951-8","article-title":"Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria","volume":"23","author":"Dickey","year":"2021","journal-title":"Genet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","article-title":"The incidence of inherited porphyrias in Europe","volume":"36","author":"Elder","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.det.2014.03.001","article-title":"The cutaneous porphyrias","volume":"32","author":"Katugampola","year":"2014","journal-title":"Dermatol. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jaad.2022.08.036","article-title":"Porphyrias Consortium of the Rare Diseases Clinical Research Network. Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria","volume":"89","author":"Dickey","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e01084","DOI":"10.1002\/prp2.1084","article-title":"Absorption, metabolism, and excretion of [14C] dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers","volume":"11","author":"Tsuda","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/archderm.1991.01680030071009","article-title":"Efficiency of opaque photoprotective agents in the visible light range","volume":"127","author":"Kaye","year":"1991","journal-title":"Arch. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12714","article-title":"Narrowband ultraviolet B phototherapy in erythropoietic protoporphyria: Case series","volume":"170","author":"Sivaramakrishnan","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jama.1974.03230330034017","article-title":"\u03b2-Carotene as an oral photoprotective agent in erythropoietic protoporphyria","volume":"228","author":"Pathak","year":"1974","journal-title":"JAMA"},{"key":"ref_22","first-page":"318","article-title":"Treatment of erythropoietic protoporphyria with beta-carotene","volume":"1","year":"1984","journal-title":"Photo-Dermatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archderm.1977.01640090077011","article-title":"Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases","volume":"113","author":"Pathak","year":"1977","journal-title":"Arch. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1517\/13543784.2010.535515","article-title":"Afamelanotide, an antagonistic analog of alpha-melanocyte-stimulating hormone, dermal phototoxicity of erythropoietic protoporphyria","volume":"19","author":"Minder","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_25","first-page":"125","article-title":"Beta-carotene in the treatment of erythropoietic protoporphyria. A short review","volume":"100","author":"Krook","year":"1982","journal-title":"Acta Derm. Venereol. Suppl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-2133.1995.tb16955.x","article-title":"Narrow-band UVB (TL-01) phototherapy: An effective preventative treatment for the photodermatoses","volume":"132","author":"Collins","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"ref_27","first-page":"245","article-title":"Protoporphyrin photosensitivity cannot be attenuated by oral N-acetylcysteine","volume":"9","author":"Marx","year":"1993","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/lt.20620","article-title":"Liver transplantation for erythropoietic protoporphyria liver disease","volume":"11","author":"McGuire","year":"2005","journal-title":"Liver Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.1977.tb14273.x","article-title":"The long-term treatment with beta-carotene in erythropoietic protoporphyria: A controlled trial","volume":"97","author":"Corbett","year":"1977","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/17512433.2021.1879638","article-title":"Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria","volume":"14","author":"Wensink","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_31","unstructured":"European Medicines Agency (2023, July 24). EU\/3\/22\/2585\u2014Orphan Designation for Treatment of Erythropoietic Protoporphyria. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-22-2585."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Minder, A.-E., Schneider-Yin, X., Zulewski, H., Minder, C.E., and Minder, E.I. (2023). Afamelanotide is associated with dose-dependent protective effect from liver damage related to erythropoietic protoporphyria. Life, 13.","DOI":"10.3390\/life13041066"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1001\/jama.1991.03470190078033","article-title":"Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin","volume":"266","author":"Levine","year":"1991","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/pcmr.12257","article-title":"MC1R, the cAMP pathway, and the response to solar UV: Extending the horizon beyond pigmentation","volume":"27","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/TACG.S122030","article-title":"Advances in the management of erythropoietic protoporphyria\u2014The role of afamelanotide","volume":"9","author":"Lane","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"ref_36","unstructured":"Swetlitz, I. (2023, July 25). Clinuvel Limits the Availability of Scenesse for Rare Genetic Disease. Available online: https:\/\/www.bloomberg.com\/news\/articles\/2023-05-01\/clinuvel-limits-availability-of-scenesse-for-rare-genetic-disease#xj4y7vzkg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2174\/1389200219666180628171531","article-title":"Metabolism of peptide drugs and strategies to improve their metabolic stability","volume":"19","author":"Yao","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1002\/ski2.78","article-title":"Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist","volume":"2","author":"Suzuki","year":"2022","journal-title":"Skin Health Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cpdd.1235","article-title":"The oral bioavailability and effect of various gastric conditions on the pharmacokinetics of dersimelagon in healthy adult volunteers","volume":"12","author":"Ogawa","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mun, Y., Woo, K., and Dongyun, S. (2023). Melanocortin 1 Receptor (MC1R): Potentials as therapeutic targets. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1558.v1"},{"key":"ref_41","first-page":"95","article-title":"Melanocortin 1 Receptor: Structure, function, and regulation","volume":"7","author":"Horrell","year":"2016","journal-title":"Front. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/archderm.140.7.827","article-title":"Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers","volume":"140","author":"Dorr","year":"2004","journal-title":"Arch. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00228-023-03476-6","article-title":"Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist","volume":"79","author":"Ogasawara","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"AB92","DOI":"10.1016\/j.jaad.2022.06.400","article-title":"34420 Perspective of patients with erythropoietic protoporphyria treated with dersimelagon, a selective melanocortin-1 receptor agonist: Results of the ENDEAVOR study exit questionnaire","volume":"87","author":"Belongie","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"AB156","DOI":"10.1016\/j.jaad.2022.06.654","article-title":"33323 Dersimelagon, a melanocortin-1 receptor agonist, maintains efficacy regardless of seasons in subjects with erythropoietic protoporphyria: Results from a post hoc analysis of phase 2 clinical trial data","volume":"87","author":"Belongie","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_47","first-page":"82","article-title":"Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells","volume":"17","author":"Murata","year":"1997","journal-title":"Invasion Metastasis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-022-02899-3","article-title":"Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis","volume":"24","author":"Kondo","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_49","first-page":"775","article-title":"A review and update on melanocyte stimulating hormone therapy: Afamelanotide","volume":"12","author":"Fabrikant","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.27086","article-title":"Liver transplantation in the management of porphyria","volume":"60","author":"Singal","year":"2014","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0016-5085(86)90093-4","article-title":"Fatal liver failure in protoporphyria: Synergism between ethanol excess and the genetic defect","volume":"90","author":"Bonkovsky","year":"1986","journal-title":"Gastroenterology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:41:36Z","timestamp":1760132496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ph17010031"],"URL":"https:\/\/doi.org\/10.3390\/ph17010031","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]}}}